AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID-19 WHO ARE AT INCREASED RISK OF PROGRESSION
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: PFIZER, SLU
- Phase: III
- Execution start: 03/08/2021
- End of execution: 30/09/2022
- PI: JUAN PASQUAU LIAÑO